WolverHeme Happy Hour Podcast Por Bernard Marini Anthony Perissinotti et al. arte de portada

WolverHeme Happy Hour

WolverHeme Happy Hour

De: Bernard Marini Anthony Perissinotti et al.
Escúchala gratis

OFERTA POR TIEMPO LIMITADO. Obtén 3 meses por US$0.99 al mes. Obtén esta oferta.
Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.Bernard Marini, Anthony Perissinotti, et al. Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • Episode 38: Prophy and Pints!

    Episode 38: Prophy and Pints!
    Sep 10 2025

    We're back after a summer break! In this episode, Anthony and Bernie review the optimal approach to antimicrobial prophylaxis in hematology patients. How do you best choose prophylaxis for your patients? Where are we using data and where are we just making things up? Does everyone need antifungal, antibacterial, antiviral, and anti-PJP prophylaxis? We will demystify prophylaxis guidelines for you!

    Más Menos
    50 m
  • Episode 37: Spilling Drinks over Cytarabine Dosing

    Episode 37: Spilling Drinks over Cytarabine Dosing
    Jul 11 2025

    In this episode, Bernie and Anthony talk about some BIG changes in cytarabine dosing in AML consolidation after a recent practice changing article. Will this change your practice?


    Hunault, et al. NEJM. 2025.

    https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400326
    Más Menos
    59 m
  • Episode 36: ODAC - Our Decisions Are Confusing

    Episode 36: ODAC - Our Decisions Are Confusing
    May 28 2025

    In this episode, Bernie and Anthony are joined by the Myeloma Man Dr. Manni Mohyuddin and lymphoma expert Dr. David Russler-Germain to discuss the very recent ODAC decisions on the STARGLO (glofitamab + GemOx) and AQUILA (daratumumab for smoldering multiple myeloma) trials. Did ODAC do their due diligence, or are there double standards? There is a lot to unpack in this episode!

    Más Menos
    43 m
Todavía no hay opiniones